{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T13:41:13Z","timestamp":1784641273200,"version":"3.55.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To identify imaging biomarkers of primary tumors and lymph nodes in patients with stage III\u2013IV non-small cell lung cancer (NSCLC) and assess their predictive ability for treatment response (response vs. non-response) to immune checkpoint inhibitors (ICIs) after 6\u202fmonths.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Retrospective analysis of 83 NSCLC patients treated with ICIs. Quantitative imaging features of the maximum primary lung tumors and lymph nodes on contrast-enhanced CT imaging were extracted at baseline (time point 0, TP0) and after 2\u20133 cycles of immunotherapy (time point 1, TP1). Delta-radiomics features (delta-RFs) were defined as the net changes in radiomics features (RFs) between TP0 and TP1. Interobserver interclass coefficient (ICC) and Pearson correlation analyses were applied for feature selection, and logistic regression (LR) was used to build a model for predicting treatment response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Four and five important delta-RFs were selected to construct the nodal and tumor models, respectively. \u0394 Tumor diameter was used for constructing the clinical prediction model. The predictive efficacy of the nodal model for the treatment response status was higher than that of the tumor and clinical models. In the training set, the AUC values for the three models were 0.96 (95% CI\u202f=\u202f0.90\u20131.00), 0.86 (95% CI\u202f=\u202f0.76\u20130.95), and 0.82 (95% CI\u202f=\u202f0.71\u20130.93), respectively. In the validation set, the AUC values were 0.94 (95% CI\u202f=\u202f0.85\u20131.00), 0.77 (95% CI\u202f=\u202f0.56\u20130.98), and 0.74 (95% CI\u202f=\u202f0.48\u20131.00), respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The nodal model based on delta-RFs performed well in distinguishing responders from non-responders and could identify patients more likely to benefit from immunotherapy. Finally, the nodal model exhibited a higher classification performance than the tumor model.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1541376","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T05:22:35Z","timestamp":1743657755000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Predicting the immune therapy response of advanced non-small cell lung cancer based on primary tumor and lymph node radiomics features"],"prefix":"10.3389","volume":"12","author":[{"given":"Dong","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinna","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonggang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfeng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingting","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.lungcan.2017.11.009","article-title":"Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: current controversies and future directions","volume":"115","author":"Soo","year":"2018","journal-title":"Lung Cancer"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1200\/JCO.2017.74.3062","article-title":"Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (check mate 017 and check mate 057)","volume":"35","author":"Horn","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1148\/radiol.2015151169","article-title":"Radiomics: images are more than pictures, they are data","volume":"278","author":"Gillies","year":"2016","journal-title":"Radiology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"544339","DOI":"10.3389\/fonc.2021.544339","article-title":"A CT-based radiomics approach to predict nivolumab response in advanced non-small-cell lung cancer","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/2326-6066.CIR-19-0476","article-title":"Changes in CT radiomic features associated with lymphocyte distribution predict overall survival and response to immunotherapy in non-small cell lung cancer","volume":"8","author":"Khorrami","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1200\/EDBK_199747","article-title":"Novel quantitative imaging for predicting response to therapy: techniques and clinical applications","volume":"38","author":"Bera","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1148\/radiol.2015142920","article-title":"Stage III non-small cell lung cancer: prognostic value of FDG PET quantitative imaging features combined with clinical prognostic factors","volume":"278","author":"Fried","year":"2016","journal-title":"Radiology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1200\/JCO.2017.77.0412","article-title":"Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study","volume":"36","author":"Gettinger","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"100511","DOI":"10.1016\/j.ejro.2023.100511","article-title":"Delta-radiomics in cancer immunotherapy response prediction: a systematic review","volume":"11","author":"Abbas","year":"2023","journal-title":"Eur J Radiol Open"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ijrobp.2011.11.069","article-title":"Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung","volume":"84","author":"Suntharalingam","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.ijrobp.2019.03.036","article-title":"Integrating tumor and nodal imaging characteristics at baseline and mid-treatment computed tomography scans to predict distant metastasis in oropharyngeal cancer treated with concurrent chemoradiotherapy","volume":"104","author":"Wu","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jtho.2016.11.2226","article-title":"Radiomic-based pathological response prediction from primary tumors and lymph nodes in NSCLC","volume":"12","author":"Coroller","year":"2017","journal-title":"J Thorac Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e192859","DOI":"10.1371\/journal.pone.0192859","article-title":"18F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC)\u2014a prospective externally validated study","volume":"13","author":"Carvalho","year":"2018","journal-title":"PLoS One"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1183\/13993003.00099-2015","article-title":"Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data","volume":"46","author":"Paesmans","year":"2015","journal-title":"Eur Respir J"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"657615","DOI":"10.3389\/fonc.2021.657615","article-title":"Imaging biomarkers to predict and evaluate the effectiveness of immunotherapy in advanced non-small-cell lung cancer","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40644-019-0283-8","article-title":"A delta-radiomics model for preoperative evaluation of neoadjuvant chemotherapy response in high-grade osteosarcoma","volume":"20","author":"Lin","year":"2020","journal-title":"Cancer Imaging"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s12032-020-01359-9","article-title":"Delta-radiomics increases multicentre reproducibility: a phantom study","volume":"37","author":"Nardone","year":"2020","journal-title":"Med Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"704607","DOI":"10.3389\/fonc.2021.704607","article-title":"Exploring CT texture parameters as predictive and response imaging biomarkers of survival in patients with metastatic melanoma treated with PD-1 inhibitor nivolumab: a pilot study using a delta-radiomics approach","volume":"11","author":"Guerrisi","year":"2021","journal-title":"Front Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1186\/s12967-024-05392-4","article-title":"CT-based delta-radiomics nomogram to predict pathological complete response after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma patients","volume":"22","author":"Fan","year":"2024","journal-title":"J Transl Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"11020","DOI":"10.1117\/1.JMI.5.1.011020","article-title":"Influence of CT acquisition and reconstruction parameters on radiomic feature reproducibility","volume":"5","author":"Midya","year":"2018","journal-title":"J Med Imaging"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e169172","DOI":"10.1371\/journal.pone.0169172","article-title":"Associations of radiomic data extracted from static and respiratory-gated CT scans with disease recurrence in lung cancer patients treated with SBRT","volume":"12","author":"Huynh","year":"2017","journal-title":"PLoS One"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s00330-014-3420-6","article-title":"Quantitative CT texture and shape analysis: can it differentiate benign and malignant mediastinal lymph nodes in patients with primary lung cancer?","volume":"25","author":"Bayanati","year":"2015","journal-title":"Eur Radiol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"4727","DOI":"10.1118\/1.4926755","article-title":"The value of nodal information in predicting lung cancer relapse using 4DPET\/4DCT","volume":"42","author":"Li","year":"2015","journal-title":"Med Phys"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nrclinonc.2015.75","article-title":"PET in the management of locally advanced and metastatic NSCLC","volume":"12","author":"Grootjans","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2967\/jnumed.113.128504","article-title":"Quantitative volumetric CT-histogram analysis in N-staging of 18F-FDG-equivocal patients with lung cancer","volume":"55","author":"Flechsig","year":"2014","journal-title":"J Nucl Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1541376\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T05:22:37Z","timestamp":1743657757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1541376\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":30,"alternative-id":["10.3389\/fmed.2025.1541376"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1541376","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"article-number":"1541376"}}